Bradley McGregor, MD

Bradley McGregor, MD, discusses next steps for research with ipilimumab plus nivolumab for patients with diverse bladder cancer histologies.

Bradley McGregor, MD, discusses the rationale for investigating nivolumab plus ipilimumab in advanced, rare genitourinary malignancies.

Bradley McGregor, MD, discusses the current NCCN guideline recommendations for the treatment of patients with divergent RCC histologies.

Bradley McGregor, MD, discusses the rationale for investigating abemaciclib monotherapy in patients with clear cell renal cell carcinoma.

Bradley McGregor, MD, discusses ongoing treatment challenges and future research directions in clear cell renal cell carcinoma.

Bradley McGregor, MD, discusses the future implications of evolutions in the renal cell carcinoma treatment paradigm.

Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.

Bradley McGregor, MD, discusses the investigation of sacituzumab govitecan plus enfortumab vedotin in metastatic urothelial cancer.

Bradley McGregor, MD, discusses the DAD-IO trial of sacituzumab govitecan, enfortumab vedotin, and pembrolizumab in metastatic urothelial cancer.

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

Bradley McGregor, MD, discusses the investigation of cabozantinib plus atezolizumab in patients with non–clear cell renal cell carcinoma.

Bradley McGregor, MD, discusses the rationale behind combining belzutifan with lenvatinib in pretreated patients with advanced renal cell carcinoma with clear cell components.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Bradley McGregor, MD, reacts to treatment advances for advanced bladder cancer and shares perspective on utilizing newer, novel therapies as the field continues to evolve

Bradley McGregor, MD, discusses the potential utility of the combination of cabozantinib and nivolumab in advanced renal cell carcinoma (RCC).

Bradley McGregor, MD, discusses the need to develop novel, actionable targets in renal cell carcinoma.

Bradley McGregor, MD, discusses combination therapies with nivolumab, cabozantinib, and sunitinib in renal cell carcinoma.

Bradley McGregor, MD, discusses the challenges of developing treatment strategies for patients with non-cell clear renal cell carcinoma.

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses how to choose between combination treatments in advanced renal cell carcinoma.

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses unmet needs in advanced renal cell carcinoma (RCC).

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in renal cell carcinoma (RCC).

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses advances made in the adjuvant setting of renal cell carcinoma (RCC).

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the future of cabozantinib (Cabometyx) in renal cell carcinoma (RCC).

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the data with the combination of axitinib (Inlyta) and avelumab (Bavencio) in advanced renal cell carcinoma (RCC).

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses frontline treatment regimens in advanced renal cell carcinoma (RCC).

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the clinical implications of the FDA approval of pembrolizumab (Keytruda) and axitinib (Inlyta) in advanced renal cell carcinoma (RCC).

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses immunotherapy in rare genitourinary (GU) cancers.

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses whether patients with renal cell carcinoma (RCC) need frontline combination therapy.

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, compares recent data with combination therapy in renal cell carcinoma.